Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes

被引：14
|
作者：
Zweck, Elric [1 ]
Westenfeld, Ralf [1 ]
Szendroedi, Julia [2 ]
机构：
[1] Heinrich Heine Univ, Dusseldorf, Germany
[2] German Diabet Ctr, Dusseldorf, Germany
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2019年 / 381卷 / 21期
关键词：
GLP-1 RECEPTOR AGONISTS;
D O I：
10.1056/NEJMc1913157
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2075 / 2076
页数：2
相关论文
共 50 条
  • [41] The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
    Mads Frederik Rasmussen
    [J]. Diabetology International, 2020, 11 : 76 - 86
  • [42] Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis
    Avgerinos, Ioannis
    Michailidis, Theodoros
    Liakos, Aris
    Karagiannis, Thomas
    Matthews, David R.
    Tsapas, Apostolos
    Bekiari, Eleni
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 335 - 345
  • [43] Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
    Lunati, Maria Elena
    Cimino, Vincenzo
    Bernasconi, Davide
    Gandolfi, Alessandra
    Morpurgo, Paola Silvia
    Tinari, Camilla
    Lazzaroni, Elisa
    Baruffaldi, Laura
    Muratori, Milena
    Montefusco, Laura
    Pastore, Ida
    Rossi, Antonio
    Franzetti, Ivano Giuseppe
    Muratori, Fabrizio
    Manfrini, Roberto
    Disoteo, Olga Eugenia
    Terranova, Rosa
    Desenzani, Paolo
    Girelli, Angela
    Ghelardi, Renata
    D'Addio, Francesca
    Ben Nasr, Moufida
    Berra, Cesare
    Folli, Franco
    Bucciarelli, Loredana
    Fiorina, Paolo
    [J]. PHARMACOLOGICAL RESEARCH, 2024, 199
  • [44] A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
    Aroda, Vanita R.
    Blonde, Lawrence
    Pratley, Richard E.
    [J]. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2022, 23 (05): : 979 - 994
  • [45] Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
    Miodrag Janić
    Manfredi Rizzo
    Francesco Cosentino
    Anca Pantea Stoian
    Mojca Lunder
    Mišo Šabović
    Andrej Janež
    [J]. Diabetes Therapy, 2022, 13 : 795 - 810
  • [46] Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Cohen, Scott
    Beckey, Cherylyn
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18): : 1797 - 1797
  • [47] Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
    Singh, Sonal
    Furberg, Curt D.
    [J]. HEART, 2009, 95 (01) : 1 - 3
  • [48] Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    Wiviott, S. D.
    Raz, I.
    Bonaca, M. P.
    Mosenzon, O.
    Kato, E. T.
    Cahn, A.
    Silverman, M. G.
    Zelniker, T. A.
    Kuder, J. F.
    Murphy, S. A.
    Bhatt, D. L.
    Leiter, L. A.
    McGuire, D. K.
    Wilding, J. P. H.
    Ruff, C. T.
    Gause-Nilsson, I. A. M.
    Fredriksson, M.
    Johansson, P. A.
    Langkilde, A-M.
    Sabatine, M. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (04): : 347 - 357
  • [49] Canagliflozin and cardiovascular outcomes in Type 2 diabetes
    Sarraju, Ashish
    Spencer-Bonilla, Gabriela
    Rodriguez, Fatima
    Mahaffey, Kenneth W.
    [J]. FUTURE CARDIOLOGY, 2020, 17 (01) : 39 - 48
  • [50] Empagliflozin and cardiovascular outcomes in type 2 diabetes
    Gregory B. Lim
    [J]. Nature Reviews Cardiology, 2016, 13 (1) : 3 - 3
12345